Previous 10 | Next 10 |
– Part 2 efficacy portion of EnACT expected to commence Q1 2020 – BEDMINSTER, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that the independent Data Safety Monitoring Board (DSMB) for the EnACT study has c...
IVERIC bio (NASDAQ: ISEE ) initiated with Outperform rating and $15 (123% upside) price target at Cowen and Company. More news on: IVERIC bio, Inc., Matinas BioPharma Holdings, Inc., Pacira BioSciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Matinas BioPharma (NYSEMKT: MTNB ) is up 4% postmarket following a start at Buy by SunTrust Robinson Humphrey. More news on: Matinas BioPharma Holdings, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Matinas BioPharma Holdings (NYSE American: MTNB), a clinical-stage biopharmaceutical company, recently closed its $50 million follow-on. The underwritten public offering consisted of 32,260,000 shares of the company’s common stock that were sold at a public offering price of $1.55 per s...
A flurry of events have hit the omega-3 landscape on January 13. Long story short, it looks like Amarin ( AMRN ) will be able to rapidly dominate the prescription omega-3 market over the course of 2020 and for the foreseeable future. Quick intro to omega-3s As a quick reminder, the main ma...
BEDMINSTER, N.J., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the closing of its underwritten registered public o...
Shares of Matinas Biopharma (NYSEMKT: MTNB) fell over 23% today after the company announced the pricing of a public stock offering. The clinical-stage pharmaceutical specialist will offer up to 37.1 million shares at $1.55 apiece. The offering could raise gross proceeds of up to $57.5 millio...
Gainers: Sorrento Therapeutics (NASDAQ: SRNE ) +38% . More news on: Sorrento Therapeutics, Inc., Ultragenyx Pharmaceutical Inc., Venus Concept Inc., Stocks on the move, Read more ...
Portola Pharmaceuticals (NASDAQ: PTLA ) -41% on preliminary Q4 and FY 2019 results. More news on: Portola Pharmaceuticals, Inc., cbdMD, Inc., Naked Brand Group Limited, Stocks on the move, Read more ...
Matinas BioPharma Holdings (NYSEMKT: MTNB ) has priced its public offering of 32.26M common shares at $1.55 per share for expected gross proceeds of ~$50M. More news on: Matinas BioPharma Holdings, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...